ACE I/D genotype associates with strength in sarcopenic men but not with response to ACE inhibitor therapy in older adults with sarcopenia: Results from the LACE trial.

<h4>Background</h4>Angiotensin II (AII), has been suggested to promote muscle loss. Reducing AII synthesis, by inhibiting angiotensin converting enzyme (ACE) activity has been proposed as a method to inhibit muscle loss. The LACE clinical trial was designed to determine whether ACE inhib...

Full description

Bibliographic Details
Main Authors: Christos Rossios, Tufail Bashir, Marcus Achison, Simon Adamson, Asangaedem Akpan, Terry Aspray, Alison Avenell, Margaret M Band, Louise A Burton, Vera Cvoro, Peter T Donnan, Gordon W Duncan, Jacob George, Adam L Gordon, Celia L Gregson, Adrian Hapca, Cheryl Hume, Thomas A Jackson, Simon Kerr, Alixe Kilgour, Tahir Masud, Andrew McKenzie, Emma McKenzie, Harnish Patel, Kristina Pilvinyte, Helen C Roberts, Avan A Sayer, Karen T Smith, Roy L Soiza, Claire J Steves, Allan D Struthers, Divya Tiwari, Julie Whitney, Miles D Witham, Paul R Kemp
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0292402&type=printable